Midodrine for female incontinence: a preliminary report

Area of Science:

• Urology
• Pharmacology
• Gynecology

Background:

• Stress urinary incontinence (SUI) affects many women, impacting quality of life.
• Current treatments for SUI have varying efficacy and side effect profiles.
• Adrenergic agents are explored for their potential to improve urethral closure mechanisms.

Purpose of the Study:

• To evaluate the efficacy of midodrine in treating stress urinary incontinence.
• To assess the urodynamic effects of oral midodrine administration in women with SUI.
• To determine if midodrine can improve urethral closure pressure and urinary flow parameters.

Main Methods:

• A study involving 26 women aged 26-60 diagnosed with stress incontinence.
• Urodynamic investigations were performed before and after oral administration of 5 mg midodrine.
• Midodrine, an alpha-adrenergic stimulant, was administered daily.

Main Results:

• A statistically significant increase in maximum urethral closing pressure was observed post-treatment.
• A trend towards increased flow time and maximum flow rate was noted, though not statistically significant.
• No adverse events were reported during the study period.

Conclusions:

• Oral midodrine administration appears to be a promising treatment for stress urinary incontinence.
• Midodrine effectively enhances maximum urethral closing pressure, a key factor in continence.
• Further research is warranted to confirm long-term efficacy and optimal dosing.